Sai Life Sciences Earns High Credit Ratings from ICRA

Sai Life Sciences Limited has secured a significant long-term credit rating of 'AA (Stable)' for its fund-based instruments and 'A1+ (Stable)' for its non-fund-based instruments from ICRA Limited. The total value of these rated facilities amounts to ₹768.60 crore, reflecting the rating agency's confidence in the company's financial strength and creditworthiness.

Reader Takeaway: Strong 'AA (Stable)' credit rating for ₹768.6 Cr facilities signals financial strength; ICRA's ongoing surveillance remains a key watchpoint.

What just happened (today’s filing)

The credit rating agency ICRA Limited has assigned 'AA (Stable)' for Sai Life Sciences' long-term fund-based instruments and 'A1+ (Stable)' for its short-term non-fund-based instruments. The total aggregate value of these rated instruments is ₹768.60 crore.

These ratings were assigned on February 25, 2026, with the rating letter dated February 26, 2026.

Why this matters

Securing high credit ratings like 'AA' and 'A1+' is a strong endorsement of a company's financial health and stability. It signifies a low risk of default to lenders and investors.

These ratings can lead to lower borrowing costs, easier access to capital for future expansion or operational needs, and enhanced confidence among stakeholders, including customers and partners.

The backstory (grounded)

Sai Life Sciences, a Hyderabad-based CRDMO founded in 1999, is a significant player in drug discovery, development, and manufacturing for global innovators.

The company has demonstrated robust financial growth, reporting a 16% increase in FY25 revenue to ₹1695 Cr and a 105% surge in PAT to ₹170 Cr.

Furthermore, Sai Life Sciences has actively managed its debt, repaying ₹585.7 Cr out of a planned ₹720 Cr from IPO proceeds by December 2024, with full repayment in January 2025, anticipating reduced finance costs from FY26.

Significant capital expenditure of ₹408 Cr was allocated in FY25, focusing on enhancing manufacturing capacity and discovery capabilities.

What changes now

Shareholders can anticipate improved financial flexibility for Sai Life Sciences, potentially leading to better access to debt financing at competitive rates.

The strong credit profile may bolster investor confidence and could positively influence the company's market valuation and its ability to attract strategic partnerships or acquisitions.

Risks to watch

ICRA may review or revise ratings if new information becomes available, required information is not provided, or other circumstances impacting the company arise. [cite:Filing]

Any default or delay in repaying principal or interest on rated or other debt instruments poses a risk. [cite:Filing]

Proposals for rescheduling debt repayments or occurrences of significant events that could impede fundraising capabilities, such as restrictions on issuing debt securities, are also factors to monitor. [cite:Filing]

Peer comparison

Sai Life Sciences' 'AA (Stable)' rating places it in a strong financial standing, comparable to other leading pharmaceutical entities.

APL Healthcare Limited, a subsidiary of Aurobindo Pharma, holds ratings of 'IND AA-' and 'IND A1+'. Torrent Pharmaceuticals has 'IND AA+' and 'IND A1+' ratings. The Akums Drugs & Pharmaceuticals Group also holds similar ratings of '[ICRA]AA(Stable)' and '[ICRA]A1+'.

These peers also maintain strong credit profiles, underscoring the robust financial health prevalent in the sector for well-managed companies.

Context metrics (time-bound)

As of FY25, Sai Life Sciences maintained a healthy debt-to-equity ratio of 0.06 and an interest coverage ratio of 18.5x, indicating strong debt servicing capacity.

In comparison, peers like APL Healthcare aimed for a net leverage below 1.5x in FY25, while Akums Group had a total debt/OPBDITA of 1.2 times as of March 31, 2024.

What to track next

ICRA will conduct surveillance of the assigned ratings, typically within one year from the communication date. [cite:Filing]

Investors will monitor the utilization of these credit facilities and how effectively Sai Life Sciences leverages them for strategic growth initiatives.

Future financial results, particularly those demonstrating sustained revenue growth, profitability, and continued prudent debt management, will be crucial.